- Home
- A-Z Publications
- Current Neuropharmacology
- Previous Issues
- Volume 15, Issue 7, 2017
Current Neuropharmacology - Volume 15, Issue 7, 2017
Volume 15, Issue 7, 2017
-
-
Biological Drugs in Guillain-Barryndrome: An Update
Background: Guillain-Barryndrome (GBS) is currently considered the most common global cause of acute flaccid paralysis. Currently, standard therapy for Guillain-Barryndrome includes intravenous immunoglobulin or plasma exchange. Despite medical advances regarding these treatments, many treated patients do not reach full recovery. Therefore several biological agents have attracted the attentions from res Read More
-
-
-
Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Background: Uveitis and optic neuritis are prevalent ocular inflammatory diseases, and highly damaging ocular conditions. Both diseases are currently treated with corticosteroids, but they do not have adequate efficacy and are often associated with severe side effects. Thus, uveitis and optic neuritis remain a challenging field to ophthalmologists and a significant public health concern. Objective: This review summarizes fi Read More
-
-
-
Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
More LessBackground: Ketamine has been reported to exert rapid and sustained antidepressant effects in patients with depression, including patients with treatment-resistant depression. However, ketamine has several drawbacks such as psychotomimetic/dissociative symptoms, abuse potential and neurotoxicity, all of which prevent its routine use in daily clinical practice. Methods: Therefore, development of novel agents with fewer s Read More
-
-
-
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Authors: Zoya Marinova, De-Maw Chuang and Naomi FinebergObjective: Obsessive-compulsive disorder (OCD) is a mental disease commonly associated with severe distress and impairment of social functioning. Serotonin reuptake inhibitors and/or cognitive behavioural therapy are the therapy of choice, however up to 40% of patients do not respond to treatment. Glutamatergic signalling has also been implicated in OCD. The aim of the current study was to review the clinical Read More
-
-
-
The Infectious Etiology of Alzheimer's Disease
Authors: Marta Sochocka, Katarzyna Zwolinska and Jerzy LeszekBackground: Inflammation is a part of the first line of defense of the body against invasive pathogens, and plays a crucial role in tissue regeneration and repair. A proper inflammatory response ensures the suitable resolution of inflammation and elimination of harmful stimuli, but when the inflammatory reactions are inappropriate it can lead to damage of the surrounding normal cells. The relationship between infe Read More
-
-
-
Mechanisms of Melatonin in Alleviating Alzheimer's Disease
Alzheimer's disease (AD) is a chronic, progressive and prevalent neurodegenerative disease characterized by the loss of higher cognitive functions and an associated loss of memory. The thus far “incurable” stigma for AD prevails because of variations in the success rates of different treatment protocols in animal and human studies. Among the classical hypotheses explaining AD pathogenesis, the amyloid hypothesis is currently Read More
-
-
-
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
More LessBackground: A resurgence of neurobiological and clinical research is currently underway into the therapeutic potential of serotonergic or ‘classical’ psychedelics, such as the prototypical psychedelic drug lysergic acid diethylamide (LSD), psilocybin (4-phosphoryloxy-N,Ndimethyltryptamine), and ayahuasca - a betacarboline- and dimethyltryptamine (DMT)-containing Amazonian beverage. The aim of this review is to introduce rea Read More
-
-
-
Cognitive Impacts of Estrogen Treatment in Androgen-Deprived Males: What Needs to be Resolved
By Erik WibowoBackground: Many prostate cancer (PCa) patients are on androgen deprivation therapy (ADT) as part of their cancer treatments but ADT may lead to cognitive impairments. ADT depletes men of both androgen and estrogen. Whether estradiol supplementation can improve cognitive impairments in patients on ADT is understudied. Objective: To summarize data on the effects of estradiol treatment on cognitive functio Read More
-
Volumes & issues
-
Volume 23 (2025)
-
Volume 22 (2024)
-
Volume 21 (2023)
-
Volume 20 (2022)
-
Volume 19 (2021)
-
Volume 18 (2020)
-
Volume 17 (2019)
-
Volume 16 (2018)
-
Volume 15 (2017)
-
Volume 14 (2016)
-
Volume 13 (2015)
-
Volume 12 (2014)
-
Volume 11 (2013)
-
Volume 10 (2012)
-
Volume 9 (2011)
-
Volume 8 (2010)
-
Volume 7 (2009)
-
Volume 6 (2008)
-
Volume 5 (2007)
-
Volume 4 (2006)
-
Volume 3 (2005)
-
Volume 2 (2004)
-
Volume 1 (2003)
Most Read This Month
Article
content/journals/cn
Journal
10
5
false
en
